Legal entity
Of the tracked stories, 3 of 3 also mention Novo Nordisk, the most common co-covered peer. corporate-law accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window.
Last mentioned: Oct 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Novo Nordisk, the most common co-covered peer. corporate-law accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. They are less corroborated than the beat average, carrying 2 original sources each against 3.2 for the same window. The 200-day window averages about 0.1 stories each week. The 6.7 average consequence score is above the beat benchmark of 6.3 in the same window. This profile follows 3 Legal stories mentioning Eli Lilly across the period from March 9, 2026 to September 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1811 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eli Lilly. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit filed
Novo Nordisk sues Eli Lilly in federal court, alleging misleading advertising.
Cease-and-desist letter
Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
High-dose Wegovy approved
Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
First NAION lawsuits filed against GLP-1 makers in New Jersey
Patients begin filing lawsuits alleging that GLP-1 drugs such as Ozempic, Wegovy, and Zepbound caused permanent vision loss and that manufacturers failed to warn about the risk.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
HIMS Launches GLP-1s
Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
Nearly 100 NAION lawsuits against Novo Nordisk and Eli Lilly test pharmaceutical failure-to-warn liability. Mixed epidemiological evidence and diabetes-related blindness risk create a dense causation battleground for mass tort litigators.
Novo Nordisk alleges Eli Lilly’s comparative advertising for Zepbound relies on outdated clinical data, violating the Lanham Act. The case could redefine how quickly pharma competitors must update ad claims when new drug formulations enter the market.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Source: wfmynews2.com · 12news.com
Eli Lilly is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
